Introduction
Angiogenesis is of critical importance in the expansion of solid tumors. 1, 2 Angiogenesis is controlled by a balance between positive and negative signals, including soluble factors, cellcell and cell-matrix interactions. 1, 2 Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are multifunctional, secreted growth factors that sustain angiogenesis by regulating various events such as cell migration, proliferation, and tube formation. 1, 2 Proteolytic degradation of the extracellular matrix (ECM) is also an important aspect of angiogenesis and is accomplished by matrix metalloproteinases (MMPs). 3, 4 One member of the MMP family, MMP-9 (gelatinase B, 92-kDa), capable of degrading type IV and V collagens, laminin and fibronectin, is expressed in vivo and in vitro by many malignant cell types, and has been associated with tumor invasion. 3, 4 Recent studies have indicated that angiogenesis may be involved in the pathogenesis of certain hematological malig- nancies, 5 such as acute lymphoblastic and myeloid leukemias (ALL and AML, respectively), [5] [6] [7] B cell non-Hodgkin lymphoma, 5, 8 myeloma, 5,9,10 myelodysplastic syndromes 5, 6, 11 and more recently B chronic lymphocytic leukemia (B-CLL). 5, 6, 12 B-CLL is characterized by an accumulation of long-lived slowdividing monoclonal B cells in the peripheral blood and their progressive infiltration of lymphoreticular tissues (bone marrow and secondary lymphoid tissues). 13 Increased angiogenesis has been observed in the bone marrow of patients with B-CLL. 6, 12 Elevated levels of bFGF and VEGF have been detected in urine and serum from patients with B-CLL. 6, 12, [14] [15] [16] B-CLL lymphocytes themselves express VEGF mRNA, produce and release VEGF protein (42-kDa, VEGF-A). 15 High intracellular levels of bFGF are found in B-CLL cells. 5, 16 Within the B cell compartment, isolated tonsillar B cells, Epstein-Barr virus (EBV)-immortalized B cells, non-Hodgkin's lymphomas, myeloma cells and Burkitt cell lines release a MMP-9 activity. [17] [18] [19] [20] [21] The identification of B-CLL-derived MMPs has not yet been investigated.
Interferons (IFNs) exert different effects, such as inhibition of proliferation, induction of differentiation and immunomodulation. 22 IFNs have been exploited in maintenance therapy for patients with various malignancies, including leukemias and carcinomas. [22] [23] [24] In this study, we analyzed the simultaneous expression of MMP-9, VEGF and bFGF in early stage B-CLL and the effects of IFNs type I and II on their expression. We report for the first time that B-CLL lymphocytes in vitro express MMP-9, the synthesis and production of which being suppressed by IFNs.
Materials and methods

Patients
Peripheral blood from 32 untreated B-CLL patients (early stage B-CLL, grade A according to Binet's classification) with hyper leukocytosis was drawn into heparin-containing tubes. All patients had typical CLL according to the international CLL workshop criteria including defined morphology and immunophenotyping (CD5
. Serum samples from patients were used to measure MMP-9 and compared with samples from healthy individuals used as controls.
Cell preparation and culture
B-CLL cells were isolated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation and used immediately. Preparations contained less than 5% CD3 + and CD14 + cells. B-CLL cells were cultured in RPMI 1640 medium containing 2 mM L-glutamine, 10 mM HEPES, 10 g/ml gentamycin and 10% heat-inactivated fetal calf serum (FCS, Gibco)
Leukemia at a seeding density of 1-2 × 10 6 cells/ml. Cell cultures were stimulated with human recombinant interferons (rIFNs) (10-10 3 U/ml) at 37°C for up to 2 days in a humidified atmosphere containing 5% CO 2 . Human rIFN-␥ (2 × 10 7 U/mg) was from Roussel-Uclaf (Romainville, France), human rIFN-␣ 2a (2 × 10 8 U/mg) was from Hoffman-La Roche (Basel, Switzerland) and human rIFN-␤ (2 × 10 8 U/mg) was from Ares-Serono (Geneva, Switzerland). For the inhibition of MMP-9 activity, neutralizing antibodies against VEGF (LD12, mIgG2b) and TNF-␣ (QRO2, goat IgG) were from R&D, Abingdon, UK.
Resting normal B cells were isolated after Ficoll-Hypaque following negative selection using beads coated with antibodies (Abs) to CD14 and CD3 (Dynal, Oslo, Norway) to remove monocytes and T cells. Negative selection of B cells was preferred to positive selection with CD19 Abs to avoid possible activation of B cells. Cell cultures were stimulated as previously described, 25 with a combination of rIL-4 (100 U/ml, Immugenex, Los Angeles, CA, USA) and Staphylococcus aureus strain Cowan I (SAC, 0.01%, Clini-Sciences, Montrouge, France) at 37°C for 2 days, to produce activated CD23 + B cells (up to 40%).
Flow cytometry analysis
Intact and permeabilized cells were immunostained as previously described. 25 Fluorescein isothiocyanate (FITC)-conjugated-CD23 (9P.25, mIgG1), phycoerythrin (PE)-CD19 (J4.119, mIgG1) and matched-isotypes were from Coulter Beckman (Margency, France). For cell permeabilization, cells were fixed in 4% formaldehyde containing 50% EtOH for 10 min at room temperature. After washing with PBS, the cells were incubated in PBS containing 0.2% Tween for 5 min at room temperature. Cells were washed and further stained with MMP-9 Ab (4H3, mIgG1, R&D) in PBS containing 0.025% Tween. After 30 min of incubation, the cells were washed twice and subsequently incubated for 30 min with PE-conjugated goat F(abЈ)2 anti-mouse IgG, washed twice, and fixed with 0.1% formaldehyde in PBS. Analysis was performed in a FACS flow cytometer analyzer (Becton Dickinson, Mountain View, CA, USA), 10 000 events were recorded and analyzed using Lysys II software (Becton Dickinson).
Enzyme-linked immunosorbent assays
The culture supernatants from normal B and B-CLL cells was harvested under sterile conditions and frozen before MMP-9, VEGF, bFGF and TNF-␣ contents were determined using commercial ELISA kits (MMP-9, VEGF, bFGF ELISA kits were provided by R&D; TNF-␣ kit was from Coulter). Controls included FCS-supplemented RPMI 1640 medium alone incubated under the same conditions. The concentrations were calculated after subtraction of the control values.
Measurement of MMP-9 gelatinolytic activity by zymography
Analysis of MMP-9 activity was carried out in 7.5% (w/v) SDSpolyacrylamide gels containing 0.1% gelatin (w/v) as The cDNAs from two representative B-CLL samples cultured for 48 h were used as templates for PCR reactions using specific primers for MMP-9, VEGF, bFGF or ␤2-microglobulin as described in Materials and methods. PCR products were run on 5% polyacrylamide gels. All the samples tested (n = 15) exhibited MMP-9 and bFGF transcripts, whereas only five samples of 15 tested showed the 204 bp VEGF transcript. (b) B-CLL cells (first column), resting B (second column) or activated B cells (third column) from normal donors were cultured for 48 h in culture medium containing 10% heat-inactivated FCS, and MMP-9, bFGF and VEGF productions (pg/ml/10 6 cells) in the culture supernatants were determined by ELISA. Controls included FCS-supplemented culture medium alone incubated under the same conditions. No MMP-9 and VEGF were detected in controls, and bFGF values were Ͻ0.2 pg/ml. Median concentrations are indicated by a horizontal line.
Leukemia described elsewhere. 26 Equal amounts of culture media (10-20 l) were applied to the gel in Laemmli sample buffer lacking ␤-mercaptoethanol. The recombinant pro-MMP-9 with a Mr 92 kDa (R&D) was used as positive control. Samples were preincubated for 60 min with 0.5 mM amino-phenylmercuric acid (APMA, Sigma Chemicals) which activates the pro-form to the activated form. Gelatinolytic activities of both pro-MMP-9 and active MMP-9 were detected as transparent bands on the background of Coomassie-blue stained gelatin. The NIH Image 1.44b11 software was used for the analysis of the bands, after acquisition in an Appligen densitometer (Oncor, Gaithersburg, MD, USA).
Figure 3
Inhibition of MMP-9 mRNA and protein expression by neutralizing TNF-␣ and VEGF antibodies. The effect of TNF-␣ and VEGF neutralization on MMP-9 expression was examined by the addition of control isotypes (polyclonal goat Ig, mIgG2b and both isotypes) or specific antibodies against TNF-␣, VEGF or both Abs (0.5 g/ml) at the initiation of culture of B-CLL cells (2 × 10 6 cells /ml). Cells were harvested at 24 h. The cDNAs of a representative patient were used as templates for PCR reactions using specific primers for MMP-9 or ␤2-microglobulin as described in Materials and methods. PCR products were run on 5% polyacrylamide gels.
RNA extraction and RT-PCR
RNA extraction from B-CLL cells and subsequent cDNA synthesis were conducted as previously described. 25 The cDNAs for human ␤ 2 -microglobulin, MMP-9, VEGF and bFGF were amplified by PCR and primers were designed according to published sequences. 18, 25, 27, 28 MMP-9 cDNA (296 bp) was amplified using the sense primer 5Ј-GGA GAC CTG AGA ACC AAT CTC-3Ј and the antisense primer 5Ј-TCC AAT AGG TGA TGT TGT CGT-3Ј. ␤ 2 -microglobulin cDNA (165 bp) was amplified using the sense primer 5Ј-CAT CCA GCG TAC TCC AAA GA-3Ј and antisense 5Ј-GAC AAG TCT GAA TGC TCC AC-3Ј. VEGF cDNA (204 bp, giving rise to the 42-kDa protein) was amplified using the sense primer 5Ј-ACA TCT TCC AGG AGT ACC CTG ATG AG-3Ј and the antisense primer 5Ј-GCA TTC ACA TTT GTT GTG CTG T-3Ј. bFGF cDNA (136 bp giving rise to the 18-kDa protein) was amplified using the sense primer 5Ј-GGC TTC TTC CTG CGC ATC CAC-3Ј and the antisense primer 5Ј-GGT AAC GGT TAG CAC ACA CTC CTT-3Ј. The PCR products were first visualized by electrophoresis in 1.2% agarose gel containing 0.2 g/ml ethidium bromide. For final detection, the PCR products were separated on 5% polyacrylamide gels and visualized using ethidium bromide. The ␤ 2 -microglobulin gene was used to normalize the PCR products. The NIH Image 1.44b11 software was used for the analysis.
Results
Detection of MMP-9 in patients with early stage B-CLL
Levels of MMP-9 were evaluated in serum samples collected from patients with early stage B-CLL or from normal donors ( Figure 1A ). The median MMP-9 level in B-CLL patients (250 ng/ml) was significantly higher (P Ͻ 0.0001) than in normal controls (67 ng/ml). Serum MMP-9 may be derived from circulating blood leukocytes. A widely feature of various cell types is their in vitro ability to release with time increased quantities of MMP-9 in absence of any inducer. 29 Preliminary experiments have shown that 24-h culture of B-CLL cells released low levels of MMP-9, the phenotypes of isolated blood cells from B-CLL patients were then determined at 24-h culture. As shown in Figure 1B (panel b) , cells from one representative patient showed a costaining of CD19 and CD23 (90%) confirming that tumor leukocytes are mainly represented by activated B lineage cells. In parallel, using a permeabilization technique to allow MMP-9 intracellular staining, we showed that these CD19-CD23-positive leukemic cells also stained for MMP-9 (84%) ( Figure 1B, panel c) .
Quantification of MMP-9, bFGF and VEGF levels in B-CLL cell culture supernatants
Total RNA from cultured B-CLL cells was isolated, reversetranscribed and subjected to PCR amplification. Samples were standardized for total cDNA content by assessing the presence of identical amounts of ␤ 2 -microglobulin transcripts. Two representative examples of RT-PCR products separated on polyacrylamide gels are shown in Figure 2a . MMP-9 (296 bp) and bFGF (136 bp) PCR products were detected in all the samples tested (n = 15, Figure 2a ). In contrast, B-CLL samples showed disparate patterns of 204 bp VEGF transcript, five of 15 samples tested being only clearly detectable (Figure 2a,  sample 1) .
Furthermore, we analyzed B-CLL lymphocytes for their capacity to release MMP-9, VEGF and bFGF into the culture conditioned medium (Figure 2b ). Using enzyme-linked immunosorbent assays (ELISAs), kinetic studies indicated a timedependent accumulation of the three factors in B-CLL cell supernatants (data not shown). After 48-h culture, the mean MMP-9 and bFGF concentrations for B-CLL patients were respectively 503 (158-1300) and 16.2 (0.5-41) pg/ml/10 6 cells, while little accumulation was observed in supernatants from normal (resting and activated) B cells (Figure 2b) . No significant differences between B-CLL and control B cells were observed in the production of VEGF (Figure 2b ) whose low levels (mean 1.4 pg/ml/10 6 cells, range 0-3.5), were in relationship with the low expression of VEGF transcript (Figure 2a) .
Stimulation of MMP-9 in B-CLL by endogenous TNF-␣ and VEGF
In various cell types, TNF-␣ or VEGF have been reported to upregulate the expression of MMPs including MMP-9 3, 30, 31 and we envisaged a similar mechanism for B-CLL. B-CLL lymphocytes display TNF-␣ gene and protein. [32] [33] [34] [35] We indeed found that cultured B-CLL cells produce very low amounts of TNF-␣ (around 0.3 pg/ml/10 6 cells at 48-h culture). Neutralizing antibodies (Abs) against TNF-␣ and VEGF were added to the B-CLL cultures and their respective isotypes were used as controls. No significant changes were noted with the isotypes (Figure 3a) . MMP-9 production by 24-h cultured cells was diminished by TNF-␣ Ab and to a lesser degree by VEGF Ab (Figure 3a) , and the addition of both Abs exerted a more effective inhition (Figure 3a) . PCR reactions from one representative experiment (Figure 3b ) indicated that this was reflected by mRNA inhibition. Together, these data indicate a transcriptional regulation of MMP-9 by endogenous TNF-␣ and VEGF. Figure 4a, lanes 5-7) . ELISA data showed that diminished MMP-9 gelatinolytic activity resulted from the decrease in the release of MMP-9 protein (Figure 4b) . The suppression of MMP-9 production in response to IFNs was dosedependent, maximal effects of IFN being obtained for doses of 100 U/ml for IFN-␥, whereas the IFN-␣ and ␤ effects were optimal at 1000 U/ml (Figure 4c ). PCR analysis was used to examine the steady-state MMP-9 mRNA alteration before and after IFN treatment. As shown in Figure 5 , decreased levels of MMP-9 transcripts were already evident in IFN-treated cells after 8-h incubation and persisted up to 72 h indicating that the downregulation of MMP-9 transcripts by IFNs is a rapid and long-lasting process.
Effects of IFNs on MMP-9, VEGF and bFGF expression
In contrast, the amounts of released VEGF and bFGF were not significantly affected by IFNs (Figure 6a ). The intracellular protein (Figure 6a ) and mRNA (Figure 6b ) contents of bFGF remained almost unchanged upon stimulation of B-CLL cells with IFNs. A marked elevation for VEGF mRNA was observed
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Figure 5
Effects of IFNs on MMP-9 transcripts in B-CLL cells. The cDNAs from B-CLL specimens cultured for the indicated times (8-72 h) in the absence or presence of IFNs (10 3 U/ml) were used as templates for PCR reactions using specific primers for MMP-9 and ␤2-microglobulin as described in Materials and methods. PCR products were run on 5% polyacrylamide gels.
at 8 h IFN-␣/␤ treatment (Figure 6b ) which was, however, not accompanied by any significant alteration in the amounts of intracellular VEGF (Figure 6a ).
Discussion
Tumors often progress in concert with an induction of angiogenesis. B-CLL is a hematological disorder, which has recently been associated with an increased angiogenesis. 6, 12 Enhanced MMP levels frequently correlate with tumor invasiveness and metastatic potential. 3, 4 In the present study, we detected elevated levels of MMP-9 in the serum of untreated patients with early stage B-CLL (grade A according to Binet's classification) as compared to normal donors. The situation could be different in later grades B-CLL (B and C) and after bone marrow infiltration where other angiogenic factors could be involved. Anyway, a detailed analysis of the elevation of sera MMP-9 levels in association with the clinical outcome and the grade Leukemia (10 3 U/ml) were used as templates for PCR reactions using specific primers for VEGF or bFGF as described in Materials and methods. PCR products were run on 5% polyacrylamide gels. ␤2-microglobulin transcripts are shown in Figure 5 .
could be potentially useful for the diagnosis and the monitoring of the patients.
One important point to address was the identification of MMP-9 producing cells in these B-CLL patients. Possible candidates were the circulating tumoral cells themselves mainly represented by CD19 + CD23 +high B lymphocytes. We clearly demonstrated that CD19 + CD23 + B cells stain for MMP-9, synthesize and secrete MMP-9. Others have shown that B-CLL lymphocytes produce bFGF, VEGF and TNF-␣. 15, 16, 32, 35 The present data are in agreement with these observations and reveal new findings with regard to normal counterpart B lymphocytes. We indeed observed that B lineage cells from healthy donors produce significantly low amounts of MMP-9 and bFGF as compared to malignant B-CLL cells. Thus, the increased sensitivity of B-CLL lymphocytes to produce MMP-9 and bFGF, in relation to their enhanced concentrations in the serum of B-CLL patients, appears to be an inherent property of the disease. With regard to VEGF, Chen et al 15 previously showed that VEGF production in B-CLL cultures was not due to contamination by non-B-CLL cells, but was produced by the B-CLL cells themselves. We confirmed by ELISA that B-CLL cells produce very low amounts of VEGF with a median level almost similar to that detected in normal B cells.
MMP-9 from various cell types is upregulated by soluble factors (IL-1␣, IL-1␤, IL-8, TNF-␣, VEGF), by cell-cell and cell-ECM contact. 3, 4, 30, 31, 36 The promoter of MMP-9 possesses several functional enhancer element binding sites including an NF-B site, 36 and TNF-␣ may activate or induce MMP-9 expression through pathways leading to activation of NF-B. 36 Moreover, high levels of nuclear NF-B-binding activity is detected in fresh B-CLL cells. 37 With the use of neutralizing antibodies, we demonstrate that B-CLL derived TNF-␣ and VEGF were sufficient to upregulate MMP-9.
With regard to angiogenesis and invasion, the model in Figure 7 describes our present knowledge of B-CLL lymphocyte behavior. B-CLL-derived VEGF was recently shown to stimulate in vitro endothelial cell proliferation, and to have angiogenic activity in the chick chorioallantoic membrane assay. 15 Little is known however about the clinical significance of high levels of serum bFGF in B-CLL. 6, 16 VEGF and bFGF from other sources are able to stimulate endothelial 1,2 or hematopoietic cell growth (including hematopoietic stem cells, AML cells and megakariocytes). 5, 31, 38 Whether VEGF, TNF-␣ and bFGF
Figure 7
Schematic representation of MMP-9 regulation in B-CLL lymphocytes. B-CLL lymphocytes release MMP-9, VEGF, bFGF and TNF-␣. TNF-␣ and VEGF upregulate MMP-9 production. Exogenous IFNs type I and II inhibit the expression and production of MMP-9 without affecting the levels of endogenous VEGF and TNF-␣. Broken arrows represent the possible actions of B-CLL-derived VEGF, bFGF and TNF-␣ on B-CLL cell survival. +, stimulation; −, inhibition. may influence the survival of B-CLL cells has to be considered. Our preliminary experiments however suggest that B-CLLderived VEGF and TNF-␣ affect neither viability nor apoptosis of B-CLL lymphocytes (data not shown). In other cell types, MMP-9 has been shown to influence cell invasion through proteolysis of the ECM, 3, 4, 39 leading to the subsequent release of the molecules sequestered in the ECM which exert direct chemotactic and/or proliferative activities on cells. 3, 4, 40 Whether B-CLL derived MMP-9 exerts a simple mechanical role in degrading the lymphoreticular tissue, or plays a more subtle role in the tissue phase of the disease remains to be detailed.
IFNs may inhibit angiogenesis which is of critical importance in the expansion of tumors. 5, 41, 42 In vitro, IFN-␣ and IFN-␥ have anti-angiogenic activity by inhibiting migration and proliferation of endothelial cells. 23, 42 The anti-angiogenic activity of IFN-␣ has been confirmed in vivo. 42 In tumorimplanted animals, IFN-␣ has shown its efficacy in inhibiting tumor growth and/or vascularization which are accompanied by decreased expression of bFGF and MMP-9. 43, 44 In various cell types, IFNs could repress the in vitro production of MMP-9 [45] [46] [47] [48] [49] and bFGF, 45, 50, 51 whereas opposite effects of IFNs were observed on VEGF expression. 45 52,53 In therapy for B-CLL, IFN-␣ achieved a partial response in 25 to 50% of previously untreated B-CLL patients with early-stage disease and with no evidence for a favorable influence on outcome. 54 We show here that in vitro IFNs type I and II inhibit MMP-9 expression at the transcriptional level, while having no effect on the production of the other pro-angiogenic factors bFGF, VEGF and TNF-␣, predicted for disease recurence. 5, 6, 12 Taken together, these results can help to explain the lack of IFN therapeutic efficacy in B-CLL patients.
In summary, the present study demonstrates for the first time enhanced levels of MMP-9 in the serum of patients with B-CLL, and in B-CLL lymphocytes. Although the relevance of our observations remain to be established in vivo, one may postulate that released MMP-9 participates in tissue infiltration of leukemic cells. The mechanisms by which IFNs mediate MMP inhibition are currently under investigation.
